{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:51:36Z","timestamp":1773424296093,"version":"3.50.1"},"reference-count":51,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,8,14]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>At current prices, ibrutinib is not a cost-effective initial CLL therapy in older patients without 17p deletion. The cost of ibrutinib would need to be &lt;$6800 per month to be cost-effective.<\/jats:p>","DOI":"10.1182\/bloodadvances.2017015461","type":"journal-article","created":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T16:18:50Z","timestamp":1536941930000},"page":"1946-1956","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":43,"title":["Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p"],"prefix":"10.1182","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7897-919X","authenticated-orcid":false,"given":"James I.","family":"Barnes","sequence":"first","affiliation":[{"name":"Veterans Affairs Palo Alto Health Care System, Palo Alto, CA;"},{"name":"Center for Primary Care and Outcomes Research\/Center for Health Policy, Department of Medicine, Stanford University School of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasu","family":"Divi","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Begaye","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Management Science and Engineering, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Coutre","sequence":"additional","affiliation":[{"name":"Division of Hematology, Stanford University School of Medicine, Stanford University, Stanford, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas K.","family":"Owens","sequence":"additional","affiliation":[{"name":"Veterans Affairs Palo Alto Health Care System, Palo Alto, CA;"},{"name":"Center for Primary Care and Outcomes Research\/Center for Health Policy, Department of Medicine, Stanford University School of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy D.","family":"Goldhaber-Fiebert","sequence":"additional","affiliation":[{"name":"Center for Primary Care and Outcomes Research\/Center for Health Policy, Department of Medicine, Stanford University School of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2018,8,10]]},"reference":[{"issue":"1","key":"2019111616034428300_B1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"2019111616034428300_B2","unstructured":"National Cancer Institute, Surveillance, Epidemiology, and End Results. Cancer Stat Facts: Leukemia\u2014Chronic Lymphocytic Leukemia (CLL). https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html. Accessed 13 February 2018."},{"issue":"1","key":"2019111616034428300_B3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111616034428300_B4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111616034428300_B5","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111616034428300_B6","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.234.234","article-title":"Updated efficacy and safety from the phase 3 Resonate-2 study: Ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia\/small lymphocytic leukemia [abstract]","volume":"128","author":"Barr","year":"2016","journal-title":"Blood"},{"key":"2019111616034428300_B7","article-title":"Long-term efficacy and safety of ibrutinib in CLL\/SLL patients","author":"Hillmen"},{"key":"2019111616034428300_B8","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (Version 2.2017, 21 February 2017). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf. Accessed 2 August 2017."},{"key":"2019111616034428300_B9","unstructured":"IBM Micromedex Web Applications Access. MICROMEDEX Ibrutinib Pricing. http:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/. Accessed 17 March 2017."},{"issue":"3","key":"2019111616034428300_B10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1200\/JOP.2014.002469","article-title":"Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels","volume":"11","author":"Shanafelt","year":"2015","journal-title":"J Oncol Pract"},{"issue":"2","key":"2019111616034428300_B11","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2016.68.2856","article-title":"Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111616034428300_B12","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111616034428300_B13","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/leu.2015.14","article-title":"Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study","volume":"29","author":"Goede","year":"2015","journal-title":"Leukemia"},{"issue":"23","key":"2019111616034428300_B14","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.1733.1733","article-title":"Updated survival analysis from the CLL11 Study: Obinutuzumab versus rituximab in chemoimmunotherapy-treated patients with chronic lymphocytic leukemia [abstract]","volume":"126","author":"Goede","year":"2015","journal-title":"Blood"},{"issue":"24","key":"2019111616034428300_B15","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111616034428300_B16","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.536.536","article-title":"Long-term survival analysis of the North American Intergroup Study C9011 comparing fludarabine (F) and chlorambucil (C) in previously untreated patients with chronic lymphocytic leukemia (CLL) [abstract]","volume":"114","author":"Rai","journal-title":"Blood"},{"key":"2019111616034428300_B17","unstructured":"TreeAge Pro, R1.2. Williamstown, MA: TreeAge Software; 2018."},{"issue":"20","key":"2019111616034428300_B18","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2014-06-583765","article-title":"Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)","volume":"124","author":"Tam","year":"2014","journal-title":"Blood"},{"key":"2019111616034428300_B19","unstructured":"Centers for Disease Control and Prevention\/National Center for Health Statistics, National Vital Statistics System. Mortality. 2009. https:\/\/www.cdc.gov\/nchs\/data\/dvs\/LEWK3_2009.pdf. Accessed 10 January 2017."},{"issue":"2","key":"2019111616034428300_B20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/bjh.13824","article-title":"The long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years","volume":"172","author":"Else","year":"2016","journal-title":"Br J Haematol"},{"key":"2019111616034428300_B21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/CLEP.S47385","article-title":"Epidemiology of atrial fibrillation: European perspective","volume":"6","author":"Zoni-Berisso","year":"2014","journal-title":"Clin Epidemiol"},{"key":"2019111616034428300_B22","unstructured":"US Department of Health and Human Services, Agency for Healthcare Research and Quality. Using appropriate price indices for expenditure comparisons. https:\/\/meps.ahrq.gov\/about_meps\/Price_Index.shtml#a3. Accessed 3 March 2017."},{"key":"2019111616034428300_B23","unstructured":"Federal Reserve Bank of St. Louis, Economic Research, US Bureau of Economic Analysis. Personal consumption expenditures: Services: Health care (chain-type price index). 2017. https:\/\/fred.stlouisfed.org\/series\/DHLCRG3A086NBEA. Accessed 3 March 2017."},{"key":"2019111616034428300_B24","first-page":"201","article-title":"Estimating costs and valuations of non-health benefits. In: Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, et al, eds. Cost-Effectiveness in Health and Medicine","author":"Basu","year":"2016"},{"key":"2019111616034428300_B25","unstructured":"US Department of Veterans Affairs, Health Economics Resource Center. Determining the cost of pharmaceuticals for a cost-effectiveness analysis. http:\/\/www.herc.research.va.gov\/include\/page.asp?id=pharmaceutical-costs. Accessed 9 January 2017."},{"key":"2019111616034428300_B26","unstructured":"Congress of the United States, Congressional Budget Office. Prices for brand-name drugs under selected federal programs. 2005. https:\/\/www.cbo.gov\/sites\/default\/files\/cbofiles\/ftpdocs\/64xx\/doc6481\/06-16-prescriptdrug.pdf. Accessed 10 January 2017."},{"issue":"5","key":"2019111616034428300_B27","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jval.2012.03.1389","article-title":"Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis","volume":"15","author":"Woods","year":"2012","journal-title":"Value Health"},{"issue":"2","key":"2019111616034428300_B28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1377\/hlthaff.2014.1371","article-title":"Medicare per capita spending by age and service: new data highlights oldest beneficiaries","volume":"34","author":"Neuman","year":"2015","journal-title":"Health Aff (Millwood)"},{"issue":"5","key":"2019111616034428300_B29","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3109\/10428194.2014.961012","article-title":"Health state utilities for chronic lymphocytic leukemia: importance of prolonging progression-free survival","volume":"56","author":"Kosmas","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2019111616034428300_B30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40273-015-0332-5","article-title":"Cost effectiveness of ofatumumab plus chlorambucil in first-line chronic lymphocytic leukaemia in Canada","volume":"34","author":"Herring","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"2019111616034428300_B31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1477-7525-8-50","article-title":"Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study","volume":"8","author":"Beusterien","year":"2010","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"2019111616034428300_B32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/0272989X04273139","article-title":"Impact of generic drug entry on cost-effectiveness analysis","volume":"25","author":"Shih","year":"2005","journal-title":"Med Decis Making"},{"issue":"1","key":"2019111616034428300_B33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11584230-000000000-00000","article-title":"Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis","volume":"29","author":"Hoyle","year":"2011","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"2019111616034428300_B34","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMp1206573","article-title":"Use patents, carve-outs, and incentives--a new battle in the drug-patent wars","volume":"367","author":"Rai","year":"2012","journal-title":"N Engl J Med"},{"key":"2019111616034428300_B35","article-title":"Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations","author":"Department of Health and Human Services, US Food and Drug Administration"},{"issue":"5","key":"2019111616034428300_B36","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1377\/hlthaff.2015.1145","article-title":"Steady increase in prices for oral anticancer drugs after market launch suggests a lack of competitive pressure","volume":"35","author":"Bennette","year":"2016","journal-title":"Health Aff (Millwood)"},{"issue":"12","key":"2019111616034428300_B37","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/cncr.30596","article-title":"Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"issue":"9980","key":"2019111616034428300_B38","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"key":"2019111616034428300_B39","first-page":"796","article-title":"Updating cost-effectiveness\u2014The curious resilience of the $50,000-per-QALY threshold","volume-title":"N Engl J Med","author":"Neumann","year":"2014"},{"issue":"2","key":"2019111616034428300_B40","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.clml.2017.12.005","article-title":"Cost-effectiveness of ibrutinib compared with obinutuzumab with chlorambucil in untreated chronic lymphocytic leukemia patients with comorbidities in the United Kingdom","volume":"18","author":"Sinha","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2019111616034428300_B41","unstructured":"National Institute for Health and Care Excellence. The guidelines manual, 2012. https:\/\/www.nice.org.uk\/process\/pmg6\/chapter\/assessing-cost-effectiveness. Accessed 29 May 2018."},{"key":"2019111616034428300_B42","author":"Neumann","year":"2016","edition":"2nd ed."},{"issue":"19","key":"2019111616034428300_B43","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJMp1512750","article-title":"New math on drug cost-effectiveness","volume":"373","author":"Bach","year":"2015","journal-title":"N Engl J Med"},{"key":"2019111616034428300_B44","unstructured":"US National Library of Medicine, ClinicalTrials.gov. Elevate CLL R\/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia. https:\/\/clinicaltrials.gov\/show\/NCT02477696. Accessed 16 February 2018."},{"key":"2019111616034428300_B45","unstructured":"US National Library of Medicine, ClinicalTrials.gov. Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CAPTIVATE). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02910583. Accessed 16 February 2018."},{"key":"2019111616034428300_B46","unstructured":"US National Library of Medicine, ClinicalTrials.gov. Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02756897. Accessed 16 February 2018."},{"issue":"5","key":"2019111616034428300_B47","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jval.2016.04.018","article-title":"Cost-effectiveness and clinical practice guidelines: have we reached a tipping point?\u2014An overview","volume":"19","author":"Garrison","year":"2016","journal-title":"Value Health"},{"issue":"21","key":"2019111616034428300_B48","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.jacc.2014.03.016","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines","volume":"63","author":"Anderson","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2019111616034428300_B49","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"2019111616034428300_B50","unstructured":"Centers for Medicare & Medicaid Services, CMS.gov. 2017 ASP Drug Pricing Files. https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Part-B-Drugs\/McrPartBDrugAvgSalesPrice\/2017ASPFiles.html. Accessed 3 April 2017."},{"key":"2019111616034428300_B51","unstructured":"IBM Micromedex Web Applications Access. MICROMEDEX Cost of Chlorambucil. http:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/. Accessed 11 January 2017."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/15\/1946\/881401\/advances015461.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/15\/1946\/881401\/advances015461.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T16:04:16Z","timestamp":1573920256000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/15\/1946\/15960\/Costeffectiveness-of-ibrutinib-as-firstline"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,10]]},"references-count":51,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2018,8,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2017015461","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,10]]}}}